View ValuationThis company has been acquiredThe company may no longer be operating, as it has been acquired. Find out why through their latest events.See Latest EventsR1 RCM 将来の成長Future 基準チェック /46R1 RCM利益と収益がそれぞれ年間62.1%と12.2%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に4.9% 62.7%なると予測されています。主要情報62.1%収益成長率62.70%EPS成長率Healthcare 収益成長18.4%収益成長率12.2%将来の株主資本利益率4.93%アナリストカバレッジGood最終更新日19 Nov 2024今後の成長に関する最新情報Major Estimate Revision • Oct 23Consensus EPS estimates fall by 58%The consensus outlook for fiscal year 2024 has been updated. 2024 expected loss increased from -US$0.209 to -US$0.329 per share. Revenue forecast of US$2.55b unchanged since last update. Healthcare industry in the US expected to see average net income growth of 27% next year. Consensus price target of US$14.70 unchanged from last update. Share price was steady at US$14.24 over the past week.お知らせ • Oct 22R1 RCM Inc. Provides Unaudited Preliminary Financial Guidance for the Fiscal Quarter Ended September 30, 2024R1 RCM Inc. provided unaudited preliminary financial guidance for the fiscal quarter ended September 30, 2024. For the period, the company expects Net service revenue to be $643.0 million to $658.0 million and net loss to be $33.5 million to $17.5 million.Major Estimate Revision • Sep 05Consensus EPS estimates upgraded to US$0.21 lossThe consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -US$0.27 to -US$0.207 per share. Revenue forecast unchanged from US$2.54b at last update. Healthcare industry in the US expected to see average net income growth of 29% next year. Consensus price target of US$14.73 unchanged from last update. Share price was steady at US$14.08 over the past week.Major Estimate Revision • Aug 14Consensus EPS estimates fall by 47%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from US$2.60b to US$2.54b. Losses expected to increase from US$0.18 per share to US$0.27. Healthcare industry in the US expected to see average net income growth of 29% next year. Consensus price target down from US$15.63 to US$14.73. Share price was steady at US$13.98 over the past week.Price Target Changed • Aug 04Price target decreased by 10% to US$15.03Down from US$16.71, the current price target is an average from 13 analysts. New target price is 7.0% above last closing price of US$14.05. The company is forecast to post a net loss per share of US$0.17 compared to earnings per share of US$0.0079 last year.お知らせ • May 09R1 RCM Inc. Revises Earnings Guidance for the Year 2024R1 RCM Inc. revised earnings guidance for the year 2024. For the year 2024, the company expects revenue of $2,600 million to $2,640 million compared to previous guidance of $2,625 million to $2,675 million. Net operating income of $85 million to $105 million compared to previous guidance of $105 million to $135 million.すべての更新を表示Recent updatesお知らせ • Nov 21+ 1 more updateR1 RCM Inc.(NasdaqGM:RCM) dropped from NASDAQ Composite IndexR1 RCM Inc. has been removed from Nasdaq Composite Index.お知らせ • Nov 20+ 6 more updatesR1 RCM Inc.(NasdaqGS:RCM) dropped from S&P Health Care Services Select Industry IndexR1 RCM Inc.(NasdaqGS:RCM) dropped from S&P Health Care Services Select Industry IndexReported Earnings • Nov 05Third quarter 2024 earnings: EPS and revenues exceed analyst expectationsThird quarter 2024 results: US$0.047 loss per share (down from US$0.003 profit in 3Q 2023). Revenue: US$656.8m (up 15% from 3Q 2023). Net loss: US$19.9m (down US$21.2m from profit in 3Q 2023). Revenue exceeded analyst estimates by 2.1%. Earnings per share (EPS) also surpassed analyst estimates by 61%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 98% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.Major Estimate Revision • Oct 23Consensus EPS estimates fall by 58%The consensus outlook for fiscal year 2024 has been updated. 2024 expected loss increased from -US$0.209 to -US$0.329 per share. Revenue forecast of US$2.55b unchanged since last update. Healthcare industry in the US expected to see average net income growth of 27% next year. Consensus price target of US$14.70 unchanged from last update. Share price was steady at US$14.24 over the past week.お知らせ • Oct 22R1 RCM Inc. Provides Unaudited Preliminary Financial Guidance for the Fiscal Quarter Ended September 30, 2024R1 RCM Inc. provided unaudited preliminary financial guidance for the fiscal quarter ended September 30, 2024. For the period, the company expects Net service revenue to be $643.0 million to $658.0 million and net loss to be $33.5 million to $17.5 million.Major Estimate Revision • Sep 05Consensus EPS estimates upgraded to US$0.21 lossThe consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -US$0.27 to -US$0.207 per share. Revenue forecast unchanged from US$2.54b at last update. Healthcare industry in the US expected to see average net income growth of 29% next year. Consensus price target of US$14.73 unchanged from last update. Share price was steady at US$14.08 over the past week.Major Estimate Revision • Aug 14Consensus EPS estimates fall by 47%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from US$2.60b to US$2.54b. Losses expected to increase from US$0.18 per share to US$0.27. Healthcare industry in the US expected to see average net income growth of 29% next year. Consensus price target down from US$15.63 to US$14.73. Share price was steady at US$13.98 over the past week.Reported Earnings • Aug 08Second quarter 2024 earnings: EPS exceeds analyst expectationsSecond quarter 2024 results: US$0.018 loss per share (further deteriorated from US$0.002 loss in 2Q 2023). Revenue: US$627.9m (up 12% from 2Q 2023). Net loss: US$7.60m (loss widened US$6.60m from 2Q 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 57%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 112% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.Price Target Changed • Aug 04Price target decreased by 10% to US$15.03Down from US$16.71, the current price target is an average from 13 analysts. New target price is 7.0% above last closing price of US$14.05. The company is forecast to post a net loss per share of US$0.17 compared to earnings per share of US$0.0079 last year.お知らせ • Jul 16R1 RCM Inc. to Report Q2, 2024 Results on Aug 07, 2024R1 RCM Inc. announced that they will report Q2, 2024 results Pre-Market on Aug 07, 2024お知らせ • May 09R1 RCM Inc. Revises Earnings Guidance for the Year 2024R1 RCM Inc. revised earnings guidance for the year 2024. For the year 2024, the company expects revenue of $2,600 million to $2,640 million compared to previous guidance of $2,625 million to $2,675 million. Net operating income of $85 million to $105 million compared to previous guidance of $105 million to $135 million.Reported Earnings • May 09First quarter 2024 earnings: EPS and revenues miss analyst expectationsFirst quarter 2024 results: US$0.083 loss per share (down from US$0.004 profit in 1Q 2023). Revenue: US$603.9m (up 11% from 1Q 2023). Net loss: US$35.1m (down US$36.7m from profit in 1Q 2023). Revenue missed analyst estimates by 1.2%. Earnings per share (EPS) also missed analyst estimates. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 115% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.お知らせ • Apr 13R1 RCM Inc., Annual General Meeting, May 22, 2024R1 RCM Inc., Annual General Meeting, May 22, 2024, at 10:00 US Eastern Standard Time. Agenda: To consider and approve the Election of Directors Proposal; to consider Approve our Fifth Amended and Restated 2010 Stock Incentive Plan Approve, on a non-binding, advisory basis, the compensation of our named executive officers; to consider and Ratify the selection by the audit committee of the board of directors of R1; and to consider the transact such other business as may properly come before the meeting or any adjournment or postponement thereof.お知らせ • Apr 02R1 RCM Inc. to Report Q1, 2024 Results on May 08, 2024R1 RCM Inc. announced that they will report Q1, 2024 results Pre-Market on May 08, 2024Major Estimate Revision • Mar 21Consensus EPS estimates upgraded to US$0.0021 lossThe consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -US$0.0028 to -US$0.0021 per share. Revenue forecast steady at US$2.64b. Healthcare industry in the US expected to see average net income growth of 25% next year. Consensus price target broadly unchanged at US$17.14. Share price fell 4.2% to US$13.10 over the past week.Seeking Alpha • Mar 03Voss Capital - R1 RCM Inc.: Bull Case Achievable Despite Negative SentimentSummary R1 RCM has the most complete and scalable independent solution in the marketplace, in what could prove to be a "winner take most" industry. RCM currently has terrible negative sentiment as evidenced by a massive multiple de-rating and short interest. Twelve months from now, we think the investment narrative will have transformed significantly. Read the full article on Seeking AlphaNew Risk • Feb 29New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 85% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.1x net interest cover). Minor Risk Large one-off items impacting financial results.お知らせ • Feb 29R1 RCM Inc. Provides Earnings Guidance for the Fiscal Year 2024R1 RCM Inc. provided earnings guidance for the fiscal year 2024. For the year, the company expects to generate revenue of between $2,625 million and $2,675 million and GAAP operating income of $105 million to $135 million.お知らせ • Feb 28New Mountain Partners V (AIV-D), L.P. and New Mountain Investments V, L.L.C., managed by New Mountain Capital, L.L.C. submits a non-binding proposal to acquire remaining 67.56906% stake in R1 RCM Inc. (NasdaqGS:RCM) from TowerBrook Investors, Ltd and others for approximately $4 billion.New Mountain Partners V (AIV-D), L.P. and New Mountain Investments V, L.L.C., managed by New Mountain Capital, L.L.C. submits a non-binding proposal to acquire remaining 67.56906% stake in R1 RCM Inc. (NasdaqGS:RCM) from TowerBrook Investors, Ltd and others for approximately $4 billion on February 26, 2024. New Mountain Capital will acquire all of the outstanding shares of common stock of R1 RCM Inc., that are not currently owned by CoyCo 1, L.P.(“CoyCo 1”), and CoyCo 2, L.P., (“CoyCo 2” and, together with CoyCo 1, the “Investors”) or their respective affiliates for cash consideration of $13.75 per share. The Proposal provides compelling value and immediate liquidity to the Company’s public stockholders. Specifically, $13.75 per share represents a significant premium of 35% to the closing price per share of $10.17 on January 25, 2024. As of February 23, 2024, the last trading day prior to our amended request for a waiver, $13.75 represented a more than 33% premium to the 30-day volume-weighted average price of $10.31. The proposal assumes a recapitalization of the Company’s indebtedness with new debt financing to be arranged by the New Mountain Funds. The equity financing to support the Proposal would be funded by the rollover of the Investors’ existing 32% common stock ownership interest in the Company and new cash equity to be provided or arranged by the New Mountain Funds. The consummation of the transactions contemplated by the Proposal will be conditioned upon approval by both a Special Committee comprised of disinterested directors and advised by independent legal and financial advisors and the Board of Directors. This Proposal is a non-binding expression of interest only, does not constitute an offer subject to binding acceptance, and is subject to execution of mutually acceptable definitive transaction documentation. This Proposal has been approved by New Mountain’s investment committee. Ropes & Gray LLP acted as legal advisor, Goldman Sachs & Co. LLC acted as financial advisor and J.P. Morgan Securities LLC acted as financial advisor to New Mountain in the transaction.Reported Earnings • Feb 28Full year 2023 earnings: EPS misses analyst expectationsFull year 2023 results: EPS: US$0.008 (up from US$0.18 loss in FY 2022). Revenue: US$2.25b (up 25% from FY 2022). Net income: US$3.30m (up US$66.6m from FY 2022). Profit margin: 0.1% (up from net loss in FY 2022). The move to profitability was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 60%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 82% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.お知らせ • Feb 27Coliseum Capital Issues an Open Letter to the Board of R1 RCMOn February 26, 2024, Coliseum Capital Management, LLC announced that it has issued an open letter to R1 RCM Inc.’s Board of Directors. In the letter, Coliseum Capital states that it views the offer by New Mountain Capital, L.L.C. to acquire the Company for cash consideration of $13.75 per share significantly undervalues the Company and is not in the best interest of shareholders. The letter also expresses support for the Company’s Board of Directors, management team, and strategy for shareholder value creation. Coliseum Capital encourages the Board of Directors to stand firm and require a materially higher price or reject the offer and stay the course as a public company.お知らせ • Feb 16R1 RCM Inc. Appoints Pamela L. Spikner as Principal Accounting OfficerOn February 15, 2024, the Board of Directors (the “Board”) of R1 RCM Inc. (the “Company”) appointed Pamela L. Spikner as principal accounting officer of the Company, effective immediately. Ms. Spikner’s appointment follows Mr. Evans’ notice to the Company on February 15, 2024 of his intent to retire by the end of the first quarter of 2024. The Company thanks Mr. Evans for his service and wishes him well in his retirement. Ms. Spikner, age 47, has served as the Company’s Chief Accounting Officer since July 2021. Prior to joining the Company, Ms. Spikner was Assistant Corporate Controller of Hill-Rom Holdings Inc., a medical technology provider, from July 2019 to July 2021. Ms. Spikner held various accounting leadership roles at Exelon Corporation, a utility services holding company, from September 2007 to July 2019. Ms. Spikner began her career with PricewaterhouseCoopers. Ms. Spikner holds a B.S. degree from Indiana University of Pennsylvania and is a certified public accountant and certified internal auditor.お知らせ • Jan 18+ 1 more updateR1 RCM Inc. (NasdaqGS:RCM) completed the acquisition of Acclara Solutions, LLC from Providence St. Joseph Health for $680 million.R1 RCM Inc. (NasdaqGS:RCM) entered into the Purchase Agreement to acquire Acclara Solutions, LLC from Providence St. Joseph Health for $680 million on December 5, 2023. The consideration for the acquisition will consist of $675 million in cash and the Warrant to purchase up to 12,192,000 shares of the R1 RCM Inc.’s common stock with an exercise price of $10.52 per share. R1 RCM Inc. expects to finance the cash portion of the consideration and the fees and expenses associated with the acquisition with a combination of a new incremental senior secured first lien term loan B facility, cash on hand, and borrowings under the R1 RCM Inc.’s existing revolving credit facility. Concurrently with the signing of the Purchase Agreement, the R1 RCM Inc. entered into that certain commitment letter, dated as of December 5, 2023, with JPMorgan Chase Bank, N.A., Bank of America, N.A., BofA Securities, Inc. and Barclays Bank PLC for an incremental senior secured first lien term loan B facility up to $500 million. The proceeds of the Incremental Term Loan will be used, together with cash on hand and borrowings under the R1 RCM Inc.’s existing revolving credit facility, to finance the cash consideration of the acquisition and related fees and expenses. Acclara generates ~$300M of Revenue(Acclara metrics are for the LTM ended June 30, 2023 inclusive of Advata Q2 2023 annualized.) and ~$25M Adjusted EBITDA(: Acclara metrics are for the LTM ended June 30, 2023 inclusive of Advata Q2 2023 annualized and Includes expected collective synergies or contributions to revenue and Adjusted EBITDA, as applicable, from the acquisition of Acclara and the 10-year agreement with Providence). over the last twelve months. The consummation of the acquisition is subject to certain conditions, including, among other things, the receipt of regulatory approvals, entry into the Commercial Agreements, the expiration or termination of all waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the rules and regulations promulgated thereunder, and other customary closing conditions. The consummation of the acquisition is not subject to approval from the R1 RCM Inc.’s stockholders. The acquisition is expected to close in early 2024. enterview Partners LLC and J.P. Morgan acted as financial advisors to R1, and Nick Ferrer, David Martinez, Sam Hong, Chris William, Lisa McGimpsey, Carl Crow, Tom Cristy, Jennifer Understahl, Jason Elliott, Adam Weiner, and Polly Hampton of Perkins Coie LLP, Kirkland & Ellis LLP, and Baker Donelson acted as legal counsel. BDT & MSD Partners acted as financial advisor to Providence, and McDermott Will & Emery and ArentFox Schiff LLP acted as legal counsel.R1 RCM Inc. (NasdaqGS:RCM) completed the acquisition of Acclara Solutions, LLC from Providence St. Joseph Health on January 18, 2024.お知らせ • Jan 09+ 1 more updateR1 RCM Inc. to Report Q4, 2023 Results on Feb 27, 2024R1 RCM Inc. announced that they will report Q4, 2023 results on Feb 27, 2024お知らせ • Dec 20R1 RCM Inc. Appoints Clay Ashdown as DirectorOn December 18, 2023, the Board of Directors of R1 RCM Inc. appointed Clay Ashdown as a director of the Company, effective as of December 18, 2023, to serve until the Company’s 2024 Annual Meeting of Stockholders and thereafter until his successor is duly elected and qualified, or until his earlier death, resignation, or removal. Mr. Ashdown has served as Intermountain’s Chief Financial Officer since October 23, 2023, where he has accountability over all finance and related functions at Intermountain, including finance operations, financial planning, accounting and internal audit, debt and credit management, rating agency/investor relations, payer contracting, revenue cycle, risk management, construction, and real estate. Mr. Ashdown has held numerous roles at Intermountain since joining the organization in 2000 and prior to his current role, Mr. Ashdown served as the Senior Vice President of Finance Operations. Before joining Intermountain, Mr. Ashdown worked at the public accounting firm of KPMG. Mr. Ashdown graduated from the University of Utah with a degree in Accounting and a minor in Russian, and he also earned an MBA from the University of Utah.お知らせ • Dec 08R1 RCM Inc. (NasdaqGS:RCM) entered into the Purchase Agreement to acquire Acclara Solutions, LLC from Providence St. Joseph Health.R1 RCM Inc. (NasdaqGS:RCM) entered into the Purchase Agreement to acquire Acclara Solutions, LLC from Providence St. Joseph Health for $680 million on December 5, 2023. The consideration for the acquisition will consist of $675 million in cash and the Warrant to purchase up to 12,192,000 shares of the R1 RCM Inc.’s common stock with an exercise price of $10.52 per share. R1 RCM Inc. expects to finance the cash portion of the consideration and the fees and expenses associated with the acquisition with a combination of a new incremental senior secured first lien term loan B facility, cash on hand, and borrowings under the R1 RCM Inc.’s existing revolving credit facility. Concurrently with the signing of the Purchase Agreement, the R1 RCM Inc. entered into that certain commitment letter, dated as of December 5, 2023, with JPMorgan Chase Bank, N.A., Bank of America, N.A., BofA Securities, Inc. and Barclays Bank PLC for an incremental senior secured first lien term loan B facility up to $500 million. The proceeds of the Incremental Term Loan will be used, together with cash on hand and borrowings under the R1 RCM Inc.’s existing revolving credit facility, to finance the cash consideration of the acquisition and related fees and expenses. Acclara generates ~$300M of Revenue(Acclara metrics are for the LTM ended June 30, 2023 inclusive of Advata Q2 2023 annualized.) and ~$25M Adjusted EBITDA(: Acclara metrics are for the LTM ended June 30, 2023 inclusive of Advata Q2 2023 annualized and Includes expected collective synergies or contributions to revenue and Adjusted EBITDA, as applicable, from the acquisition of Acclara and the 10-year agreement with Providence). over the last twelve months. The consummation of the acquisition is subject to certain conditions, including, among other things, the receipt of regulatory approvals, entry into the Commercial Agreements, the expiration or termination of all waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the rules and regulations promulgated thereunder, and other customary closing conditions. The consummation of the acquisition is not subject to approval from the R1 RCM Inc.’s stockholders. The acquisition is expected to close in early 2024. enterview Partners LLC and J.P. Morgan acted as financial advisors to R1, and Perkins Coie LLP, Kirkland & Ellis LLP, and Baker Donelson acted as legal counsel. BDT & MSD Partners acted as financial advisor to Providence, and McDermott Will & Emery and ArentFox Schiff LLP acted as legal counsel.お知らせ • Nov 19R1 RCM Receives Notice Of Filing Delinquency from NasdaqR1 RCM Inc. announced that, as anticipated, it received a letter from Nasdaq's Listing Qualifications Department indicating that, as a result of the Company's delay in filing its Quarterly Report on Form 10-Q for the three and nine months ended September 30, 2023 (the "Form 10-Q"), the Company no longer complies with the continued listing requirements under Nasdaq Listing Rule 5250(c)(1), which requires Nasdaq-listed companies to timely file all periodic reports with the Securities and Exchange Commission (the "Commission"). On November 13, 2023, the Company filed with the Commission a Notification of Late Filing on Form 12b-25 with respect to the Form 10-Q as a result of its determination to restate certain of its previously issued financial statements. The Nasdaq notice has no immediate effect on the listing of the Company's common stock. The Nasdaq notice states that the Company is required to submit a plan to regain compliance with Nasdaq's filing requirements for continued listing within 60 calendar days of the date of the notice. Upon acceptance of the Company's compliance plan, Nasdaq is permitted to grant an extension of up to 180 days from the Form 10-Q's filing due date for the Company to regain compliance with Nasdaq's filing requirements for continued listing. The Company intends to file the Form 10-Q with the Commission as soon as practicable.お知らせ • Nov 14R1 RCM Inc. announced delayed 10-Q filingOn 11/13/2023, R1 RCM Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.Price Target Changed • Nov 03Price target decreased by 8.8% to US$19.53Down from US$21.41, the current price target is an average from 16 analysts. New target price is 69% above last closing price of US$11.53. Stock is down 22% over the past year. The company is forecast to post earnings per share of US$0.046 next year compared to a net loss per share of US$0.16 last year.お知らせ • Nov 03R1 RCM Inc. Provides Revenue Guidance for the Year 2023R1 RCM Inc. provided revenue guidance for the year 2023. For the year, the company expects Revenue of $2,255 million to $2,275 million.Reported Earnings • Nov 03Third quarter 2023 earnings released: EPS: US$0.003 (vs US$0.071 loss in 3Q 2022)Third quarter 2023 results: EPS: US$0.003 (up from US$0.071 loss in 3Q 2022). Revenue: US$572.8m (up 16% from 3Q 2022). Net income: US$1.30m (up US$30.8m from 3Q 2022). Profit margin: 0.2% (up from net loss in 3Q 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 7.0% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.Buying Opportunity • Nov 02Now 26% undervalued after recent price dropOver the last 90 days, the stock is down 37%. The fair value is estimated to be US$14.76, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Meanwhile, the company became loss making.お知らせ • Oct 26R1 RCM Inc. Announces Janie Wade Resigns from its Board of DirectorsR1 RCM Inc. announced on October 19, 2023, the company received notice that Janie Wade will be resigning from the board of directors of the Company, effective October 21, 2023, in connection with her resignation from Intermountain Health. Ms. Wade was nominated to the Board by IHC Health Services Inc. (Intermountain) pursuant to the Securities Purchase Agreement, dated as of January 23, 2018, between the Company and Intermountain. Under the terms of the Securities Purchase Agreement, Intermountain is entitled to nominate another individual to the Board upon Ms. Wade’s resignation.Buying Opportunity • Oct 18Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 35%. The fair value is estimated to be US$14.65, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Meanwhile, the company became loss making.お知らせ • Oct 17R1 RCM Inc. to Report Q3, 2023 Results on Nov 02, 2023R1 RCM Inc. announced that they will report Q3, 2023 results Pre-Market on Nov 02, 2023Recent Insider Transactions Derivative • Aug 10Lead Independent Director notifies of intention to sell stockJohn Henneman intends to sell 50k shares in the next 90 days after lodging an Intent To Sell Form on the 8th of August. If the sale is conducted around the recent share price of US$17.17, it would amount to US$859k. Since September 2022, John's direct individual holding has increased from 49.60k shares to 54.75k. Company insiders have collectively sold US$16m more than they bought, via options and on-market transactions in the last 12 months.Price Target Changed • Aug 07Price target increased by 7.8% to US$21.70Up from US$20.13, the current price target is an average from 15 analysts. New target price is 25% above last closing price of US$17.38. Stock is down 35% over the past year. The company is forecast to post earnings per share of US$0.064 next year compared to a net loss per share of US$0.16 last year.お知らせ • Aug 03R1 RCM Inc. Provides Earnings Guidance for the Year of 2023R1 RCM Inc. provided earnings guidance for the year of 2023. For the year, company expects Revenue of between $2,255 million and $2,275 million and GAAP operating income of $140 million to $155 million.Reported Earnings • Aug 02Second quarter 2023 earnings released: EPS: US$0.001 (vs US$0.069 loss in 2Q 2022)Second quarter 2023 results: EPS: US$0.001 (up from US$0.069 loss in 2Q 2022). Revenue: US$560.7m (up 43% from 2Q 2022). Net income: US$300.0k (up US$20.7m from 2Q 2022). Profit margin: 0.1% (up from net loss in 2Q 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 6.9% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.お知らせ • Jul 13R1 RCM Inc. to Report Q2, 2023 Results on Aug 02, 2023R1 RCM Inc. announced that they will report Q2, 2023 results Pre-Market on Aug 02, 2023Recent Insider Transactions • Jun 16Senior VP recently sold US$487k worth of stockOn the 12th of June, Richard Evans sold around 29k shares on-market at roughly US$16.78 per share. This transaction amounted to 20% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$3.1m more than they bought in the last 12 months.Recent Insider Transactions • May 15President recently sold US$327k worth of stockOn the 10th of May, John Sparby sold around 20k shares on-market at roughly US$16.36 per share. This transaction amounted to 7.8% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. John has been a net seller over the last 12 months, reducing personal holdings by US$2.1m.Recent Insider Transactions Derivative • May 14President notifies of intention to sell stockJohn Sparby intends to sell 20k shares in the next 90 days after lodging an Intent To Sell Form on the 10th of May. If the sale is conducted around the recent share price of US$15.71, it would amount to US$314k. Since September 2022, John's direct individual holding has increased from 163.82k shares to 254.82k. Company insiders have collectively sold US$18m more than they bought, via options and on-market transactions in the last 12 months.お知らせ • May 05R1 RCM Inc. Provides Earnings Guidance for the Year 2023R1 RCM Inc. provided earnings guidance for the year 2023. For the period, Company expects Revenue of between $2,280 million and $2,330 million. GAAP operating income of $115 million to $140 million.Reported Earnings • May 05First quarter 2023 earnings: EPS exceeds analyst expectationsFirst quarter 2023 results: EPS: US$0.001 (down from US$0.10 in 1Q 2022). Revenue: US$545.6m (up 42% from 1Q 2022). Net income: US$300.0k (down 99% from 1Q 2022). Profit margin: 0.1% (down from 7.6% in 1Q 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) exceeded analyst estimates. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 7.3% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 18% per year, which means it is tracking significantly ahead of earnings growth.Recent Insider Transactions • Feb 23CEO & Director recently bought US$1.0m worth of stockOn the 21st of February, Lee Rivas bought around 72k shares on-market at roughly US$13.93 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was Lee's only on-market trade for the last 12 months.Reported Earnings • Feb 17Full year 2022 earnings: EPS misses analyst expectationsFull year 2022 results: US$0.16 loss per share (improved from US$1.86 loss in FY 2021). Revenue: US$1.81b (up 23% from FY 2021). Net loss: US$57.6m (loss narrowed 88% from FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 18%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 7.5% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has remained flat, which means it is well ahead of earnings.お知らせ • Feb 17R1 RCM Inc. Provides Earnings Guidance for the Fiscal Year 2023R1 RCM Inc. provided earnings guidance for the fiscal year 2023. for the year, the company expects revenue of between $2,280 million and $2,330 million and GAAP operating income of $115 million to $140 million.Price Target Changed • Feb 16Price target increased by 7.3% to US$16.18Up from US$15.07, the current price target is an average from 14 analysts. New target price is 11% above last closing price of US$14.57. Stock is down 43% over the past year. The company is forecast to post a net loss per share of US$0.14 next year compared to a net loss per share of US$1.86 last year.お知らせ • Jan 27R1 RCM Inc. to Report Q4, 2022 Results on Feb 16, 2023R1 RCM Inc. announced that they will report Q4, 2022 results Pre-Market on Feb 16, 2023Major Estimate Revision • Jan 08Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 expected loss increased from -US$0.06 to -US$0.07 per share. Revenue forecast of US$1.79b unchanged since last update. Healthcare industry in the US expected to see average net income growth of 4.8% next year. Consensus price target up from US$14.00 to US$14.57. Share price rose 14% to US$12.43 over the past week.お知らせ • Jan 06+ 2 more updatesR1 RCM Inc. Announces Chief Financial Officer ChangesR1 RCM Inc. announced the appointments of Jennifer Williams as Chief Financial Officer, effective immediately. Ms. Williams will succeed Rachel Wilson who will step down from their role and remain with the Company in advisory roles to ensure a seamless transition. Ms. Williams, who previously served as Chief Financial Officer of Cloudmed, brings more than 20 years of financial planning, accounting, M&A and operational finance leadership experience across several healthcare revenue management, data analytics and technology businesses, including Change Healthcare, First Advantage, LexisNexis Risk Solutions and Ernst & Young. During her career, she has led several growth transformations, large scale integrations and an initial public offering. Jennifer Williams joined R1 following the acquisition of Cloudmed, where she served as Chief Financial Officer since July 2020. Prior to Cloudmed, Ms. Williams served as Senior Vice President and Chief Financial Officer of Corporate functions for Change Healthcare. Earlier in her career, she was the corporate controller and global finance leader at First Advantage and held financial leadership positions at LexisNexis Risk Solutions for over 10 years. She began her career with Ernst & Young. Ms. Williams has a B.S. and Master of Accountancy degrees from Auburn University and is a certified public accountant.Price Target Changed • Nov 16Price target decreased to US$15.55Down from US$30.73, the current price target is an average from 11 analysts. New target price is 71% above last closing price of US$9.07. Stock is down 65% over the past year. The company is forecast to post a net loss per share of US$0.057 next year compared to a net loss per share of US$1.86 last year.Price Target Changed • Nov 10Price target decreased to US$27.82Down from US$31.90, the current price target is an average from 11 analysts. New target price is 303% above last closing price of US$6.90. Stock is down 73% over the past year. The company is forecast to post a net loss per share of US$0.04 next year compared to a net loss per share of US$1.86 last year.業績と収益の成長予測NasdaqGS:RCM - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20263,268155459631612/31/20252,95473284435912/31/20242,552-8012625739/30/20242,464-61186291N/A6/30/20242,380-40203312N/A3/31/20242,313-33229332N/A12/31/20232,2543238340N/A9/30/20232,212-35151251N/A6/30/20232,135-6568168N/A3/31/20231,966-91-9313N/A12/31/20221,806-63-103-10N/A9/30/20221,672-1-95-2N/A6/30/20221,55645-1363N/A3/31/20221,51891189242N/A12/31/20211,475-505205257N/A9/30/20211,404-495190230N/A6/30/20211,332-512108145N/A3/31/20211,293-52662107N/A12/31/20201,270471160N/A9/30/20201,2561461121N/A6/30/20201,2501655115N/A3/31/20201,2313-1643N/A12/31/20191,186-953114N/A9/30/20191,135-221168N/A6/30/20191,084-423383N/A3/31/2019997-415499N/A12/31/2018869-64-1518N/A9/30/2018746-99-419N/A6/30/2018619-88N/A23N/A3/31/2018510-92N/A39N/A12/31/2017450-76N/A21N/A9/30/2017416-28N/A-22N/A6/30/2017418-3N/A-57N/A3/31/2017327-36N/A-116N/A12/31/201659365N/A-87N/A9/30/201655568N/A-100N/A6/30/201644517N/A-57N/A3/31/201645835N/A-8N/A12/31/2015117-84N/A-24N/A9/30/201596-107N/A-39N/A6/30/2015171-65N/A-23N/A3/31/2015208-55N/A-71N/A12/31/2014210-80N/A-77N/A9/30/2014247-56N/A-22N/A6/30/2014174-103N/A-47N/A3/31/2014490102N/A28N/A12/31/2013505130N/A54N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: RCMは今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 2.6% ) よりも高い成長率であると考えられます。収益対市場: RCM今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。高成長収益: RCM今後 3 年以内に収益を上げることが予想されます。収益対市場: RCMの収益 ( 12.2% ) US市場 ( 11.7% ) よりも速いペースで成長すると予測されています。高い収益成長: RCMの収益 ( 12.2% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: RCMの 自己資本利益率 は、3年後には低くなると予測されています ( 4.9 %)。成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/11/20 03:47終値2024/11/18 00:00収益2024/09/30年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋R1 RCM Inc. 9 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。24 アナリスト機関Vikram KesavabhotlaBairdMichael ChernyBofA Global ResearchRichard CloseCanaccord Genuity21 その他のアナリストを表示
Major Estimate Revision • Oct 23Consensus EPS estimates fall by 58%The consensus outlook for fiscal year 2024 has been updated. 2024 expected loss increased from -US$0.209 to -US$0.329 per share. Revenue forecast of US$2.55b unchanged since last update. Healthcare industry in the US expected to see average net income growth of 27% next year. Consensus price target of US$14.70 unchanged from last update. Share price was steady at US$14.24 over the past week.
お知らせ • Oct 22R1 RCM Inc. Provides Unaudited Preliminary Financial Guidance for the Fiscal Quarter Ended September 30, 2024R1 RCM Inc. provided unaudited preliminary financial guidance for the fiscal quarter ended September 30, 2024. For the period, the company expects Net service revenue to be $643.0 million to $658.0 million and net loss to be $33.5 million to $17.5 million.
Major Estimate Revision • Sep 05Consensus EPS estimates upgraded to US$0.21 lossThe consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -US$0.27 to -US$0.207 per share. Revenue forecast unchanged from US$2.54b at last update. Healthcare industry in the US expected to see average net income growth of 29% next year. Consensus price target of US$14.73 unchanged from last update. Share price was steady at US$14.08 over the past week.
Major Estimate Revision • Aug 14Consensus EPS estimates fall by 47%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from US$2.60b to US$2.54b. Losses expected to increase from US$0.18 per share to US$0.27. Healthcare industry in the US expected to see average net income growth of 29% next year. Consensus price target down from US$15.63 to US$14.73. Share price was steady at US$13.98 over the past week.
Price Target Changed • Aug 04Price target decreased by 10% to US$15.03Down from US$16.71, the current price target is an average from 13 analysts. New target price is 7.0% above last closing price of US$14.05. The company is forecast to post a net loss per share of US$0.17 compared to earnings per share of US$0.0079 last year.
お知らせ • May 09R1 RCM Inc. Revises Earnings Guidance for the Year 2024R1 RCM Inc. revised earnings guidance for the year 2024. For the year 2024, the company expects revenue of $2,600 million to $2,640 million compared to previous guidance of $2,625 million to $2,675 million. Net operating income of $85 million to $105 million compared to previous guidance of $105 million to $135 million.
お知らせ • Nov 21+ 1 more updateR1 RCM Inc.(NasdaqGM:RCM) dropped from NASDAQ Composite IndexR1 RCM Inc. has been removed from Nasdaq Composite Index.
お知らせ • Nov 20+ 6 more updatesR1 RCM Inc.(NasdaqGS:RCM) dropped from S&P Health Care Services Select Industry IndexR1 RCM Inc.(NasdaqGS:RCM) dropped from S&P Health Care Services Select Industry Index
Reported Earnings • Nov 05Third quarter 2024 earnings: EPS and revenues exceed analyst expectationsThird quarter 2024 results: US$0.047 loss per share (down from US$0.003 profit in 3Q 2023). Revenue: US$656.8m (up 15% from 3Q 2023). Net loss: US$19.9m (down US$21.2m from profit in 3Q 2023). Revenue exceeded analyst estimates by 2.1%. Earnings per share (EPS) also surpassed analyst estimates by 61%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 98% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.
Major Estimate Revision • Oct 23Consensus EPS estimates fall by 58%The consensus outlook for fiscal year 2024 has been updated. 2024 expected loss increased from -US$0.209 to -US$0.329 per share. Revenue forecast of US$2.55b unchanged since last update. Healthcare industry in the US expected to see average net income growth of 27% next year. Consensus price target of US$14.70 unchanged from last update. Share price was steady at US$14.24 over the past week.
お知らせ • Oct 22R1 RCM Inc. Provides Unaudited Preliminary Financial Guidance for the Fiscal Quarter Ended September 30, 2024R1 RCM Inc. provided unaudited preliminary financial guidance for the fiscal quarter ended September 30, 2024. For the period, the company expects Net service revenue to be $643.0 million to $658.0 million and net loss to be $33.5 million to $17.5 million.
Major Estimate Revision • Sep 05Consensus EPS estimates upgraded to US$0.21 lossThe consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -US$0.27 to -US$0.207 per share. Revenue forecast unchanged from US$2.54b at last update. Healthcare industry in the US expected to see average net income growth of 29% next year. Consensus price target of US$14.73 unchanged from last update. Share price was steady at US$14.08 over the past week.
Major Estimate Revision • Aug 14Consensus EPS estimates fall by 47%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from US$2.60b to US$2.54b. Losses expected to increase from US$0.18 per share to US$0.27. Healthcare industry in the US expected to see average net income growth of 29% next year. Consensus price target down from US$15.63 to US$14.73. Share price was steady at US$13.98 over the past week.
Reported Earnings • Aug 08Second quarter 2024 earnings: EPS exceeds analyst expectationsSecond quarter 2024 results: US$0.018 loss per share (further deteriorated from US$0.002 loss in 2Q 2023). Revenue: US$627.9m (up 12% from 2Q 2023). Net loss: US$7.60m (loss widened US$6.60m from 2Q 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 57%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 112% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.
Price Target Changed • Aug 04Price target decreased by 10% to US$15.03Down from US$16.71, the current price target is an average from 13 analysts. New target price is 7.0% above last closing price of US$14.05. The company is forecast to post a net loss per share of US$0.17 compared to earnings per share of US$0.0079 last year.
お知らせ • Jul 16R1 RCM Inc. to Report Q2, 2024 Results on Aug 07, 2024R1 RCM Inc. announced that they will report Q2, 2024 results Pre-Market on Aug 07, 2024
お知らせ • May 09R1 RCM Inc. Revises Earnings Guidance for the Year 2024R1 RCM Inc. revised earnings guidance for the year 2024. For the year 2024, the company expects revenue of $2,600 million to $2,640 million compared to previous guidance of $2,625 million to $2,675 million. Net operating income of $85 million to $105 million compared to previous guidance of $105 million to $135 million.
Reported Earnings • May 09First quarter 2024 earnings: EPS and revenues miss analyst expectationsFirst quarter 2024 results: US$0.083 loss per share (down from US$0.004 profit in 1Q 2023). Revenue: US$603.9m (up 11% from 1Q 2023). Net loss: US$35.1m (down US$36.7m from profit in 1Q 2023). Revenue missed analyst estimates by 1.2%. Earnings per share (EPS) also missed analyst estimates. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 115% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.
お知らせ • Apr 13R1 RCM Inc., Annual General Meeting, May 22, 2024R1 RCM Inc., Annual General Meeting, May 22, 2024, at 10:00 US Eastern Standard Time. Agenda: To consider and approve the Election of Directors Proposal; to consider Approve our Fifth Amended and Restated 2010 Stock Incentive Plan Approve, on a non-binding, advisory basis, the compensation of our named executive officers; to consider and Ratify the selection by the audit committee of the board of directors of R1; and to consider the transact such other business as may properly come before the meeting or any adjournment or postponement thereof.
お知らせ • Apr 02R1 RCM Inc. to Report Q1, 2024 Results on May 08, 2024R1 RCM Inc. announced that they will report Q1, 2024 results Pre-Market on May 08, 2024
Major Estimate Revision • Mar 21Consensus EPS estimates upgraded to US$0.0021 lossThe consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -US$0.0028 to -US$0.0021 per share. Revenue forecast steady at US$2.64b. Healthcare industry in the US expected to see average net income growth of 25% next year. Consensus price target broadly unchanged at US$17.14. Share price fell 4.2% to US$13.10 over the past week.
Seeking Alpha • Mar 03Voss Capital - R1 RCM Inc.: Bull Case Achievable Despite Negative SentimentSummary R1 RCM has the most complete and scalable independent solution in the marketplace, in what could prove to be a "winner take most" industry. RCM currently has terrible negative sentiment as evidenced by a massive multiple de-rating and short interest. Twelve months from now, we think the investment narrative will have transformed significantly. Read the full article on Seeking Alpha
New Risk • Feb 29New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 85% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.1x net interest cover). Minor Risk Large one-off items impacting financial results.
お知らせ • Feb 29R1 RCM Inc. Provides Earnings Guidance for the Fiscal Year 2024R1 RCM Inc. provided earnings guidance for the fiscal year 2024. For the year, the company expects to generate revenue of between $2,625 million and $2,675 million and GAAP operating income of $105 million to $135 million.
お知らせ • Feb 28New Mountain Partners V (AIV-D), L.P. and New Mountain Investments V, L.L.C., managed by New Mountain Capital, L.L.C. submits a non-binding proposal to acquire remaining 67.56906% stake in R1 RCM Inc. (NasdaqGS:RCM) from TowerBrook Investors, Ltd and others for approximately $4 billion.New Mountain Partners V (AIV-D), L.P. and New Mountain Investments V, L.L.C., managed by New Mountain Capital, L.L.C. submits a non-binding proposal to acquire remaining 67.56906% stake in R1 RCM Inc. (NasdaqGS:RCM) from TowerBrook Investors, Ltd and others for approximately $4 billion on February 26, 2024. New Mountain Capital will acquire all of the outstanding shares of common stock of R1 RCM Inc., that are not currently owned by CoyCo 1, L.P.(“CoyCo 1”), and CoyCo 2, L.P., (“CoyCo 2” and, together with CoyCo 1, the “Investors”) or their respective affiliates for cash consideration of $13.75 per share. The Proposal provides compelling value and immediate liquidity to the Company’s public stockholders. Specifically, $13.75 per share represents a significant premium of 35% to the closing price per share of $10.17 on January 25, 2024. As of February 23, 2024, the last trading day prior to our amended request for a waiver, $13.75 represented a more than 33% premium to the 30-day volume-weighted average price of $10.31. The proposal assumes a recapitalization of the Company’s indebtedness with new debt financing to be arranged by the New Mountain Funds. The equity financing to support the Proposal would be funded by the rollover of the Investors’ existing 32% common stock ownership interest in the Company and new cash equity to be provided or arranged by the New Mountain Funds. The consummation of the transactions contemplated by the Proposal will be conditioned upon approval by both a Special Committee comprised of disinterested directors and advised by independent legal and financial advisors and the Board of Directors. This Proposal is a non-binding expression of interest only, does not constitute an offer subject to binding acceptance, and is subject to execution of mutually acceptable definitive transaction documentation. This Proposal has been approved by New Mountain’s investment committee. Ropes & Gray LLP acted as legal advisor, Goldman Sachs & Co. LLC acted as financial advisor and J.P. Morgan Securities LLC acted as financial advisor to New Mountain in the transaction.
Reported Earnings • Feb 28Full year 2023 earnings: EPS misses analyst expectationsFull year 2023 results: EPS: US$0.008 (up from US$0.18 loss in FY 2022). Revenue: US$2.25b (up 25% from FY 2022). Net income: US$3.30m (up US$66.6m from FY 2022). Profit margin: 0.1% (up from net loss in FY 2022). The move to profitability was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 60%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 82% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.
お知らせ • Feb 27Coliseum Capital Issues an Open Letter to the Board of R1 RCMOn February 26, 2024, Coliseum Capital Management, LLC announced that it has issued an open letter to R1 RCM Inc.’s Board of Directors. In the letter, Coliseum Capital states that it views the offer by New Mountain Capital, L.L.C. to acquire the Company for cash consideration of $13.75 per share significantly undervalues the Company and is not in the best interest of shareholders. The letter also expresses support for the Company’s Board of Directors, management team, and strategy for shareholder value creation. Coliseum Capital encourages the Board of Directors to stand firm and require a materially higher price or reject the offer and stay the course as a public company.
お知らせ • Feb 16R1 RCM Inc. Appoints Pamela L. Spikner as Principal Accounting OfficerOn February 15, 2024, the Board of Directors (the “Board”) of R1 RCM Inc. (the “Company”) appointed Pamela L. Spikner as principal accounting officer of the Company, effective immediately. Ms. Spikner’s appointment follows Mr. Evans’ notice to the Company on February 15, 2024 of his intent to retire by the end of the first quarter of 2024. The Company thanks Mr. Evans for his service and wishes him well in his retirement. Ms. Spikner, age 47, has served as the Company’s Chief Accounting Officer since July 2021. Prior to joining the Company, Ms. Spikner was Assistant Corporate Controller of Hill-Rom Holdings Inc., a medical technology provider, from July 2019 to July 2021. Ms. Spikner held various accounting leadership roles at Exelon Corporation, a utility services holding company, from September 2007 to July 2019. Ms. Spikner began her career with PricewaterhouseCoopers. Ms. Spikner holds a B.S. degree from Indiana University of Pennsylvania and is a certified public accountant and certified internal auditor.
お知らせ • Jan 18+ 1 more updateR1 RCM Inc. (NasdaqGS:RCM) completed the acquisition of Acclara Solutions, LLC from Providence St. Joseph Health for $680 million.R1 RCM Inc. (NasdaqGS:RCM) entered into the Purchase Agreement to acquire Acclara Solutions, LLC from Providence St. Joseph Health for $680 million on December 5, 2023. The consideration for the acquisition will consist of $675 million in cash and the Warrant to purchase up to 12,192,000 shares of the R1 RCM Inc.’s common stock with an exercise price of $10.52 per share. R1 RCM Inc. expects to finance the cash portion of the consideration and the fees and expenses associated with the acquisition with a combination of a new incremental senior secured first lien term loan B facility, cash on hand, and borrowings under the R1 RCM Inc.’s existing revolving credit facility. Concurrently with the signing of the Purchase Agreement, the R1 RCM Inc. entered into that certain commitment letter, dated as of December 5, 2023, with JPMorgan Chase Bank, N.A., Bank of America, N.A., BofA Securities, Inc. and Barclays Bank PLC for an incremental senior secured first lien term loan B facility up to $500 million. The proceeds of the Incremental Term Loan will be used, together with cash on hand and borrowings under the R1 RCM Inc.’s existing revolving credit facility, to finance the cash consideration of the acquisition and related fees and expenses. Acclara generates ~$300M of Revenue(Acclara metrics are for the LTM ended June 30, 2023 inclusive of Advata Q2 2023 annualized.) and ~$25M Adjusted EBITDA(: Acclara metrics are for the LTM ended June 30, 2023 inclusive of Advata Q2 2023 annualized and Includes expected collective synergies or contributions to revenue and Adjusted EBITDA, as applicable, from the acquisition of Acclara and the 10-year agreement with Providence). over the last twelve months. The consummation of the acquisition is subject to certain conditions, including, among other things, the receipt of regulatory approvals, entry into the Commercial Agreements, the expiration or termination of all waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the rules and regulations promulgated thereunder, and other customary closing conditions. The consummation of the acquisition is not subject to approval from the R1 RCM Inc.’s stockholders. The acquisition is expected to close in early 2024. enterview Partners LLC and J.P. Morgan acted as financial advisors to R1, and Nick Ferrer, David Martinez, Sam Hong, Chris William, Lisa McGimpsey, Carl Crow, Tom Cristy, Jennifer Understahl, Jason Elliott, Adam Weiner, and Polly Hampton of Perkins Coie LLP, Kirkland & Ellis LLP, and Baker Donelson acted as legal counsel. BDT & MSD Partners acted as financial advisor to Providence, and McDermott Will & Emery and ArentFox Schiff LLP acted as legal counsel.R1 RCM Inc. (NasdaqGS:RCM) completed the acquisition of Acclara Solutions, LLC from Providence St. Joseph Health on January 18, 2024.
お知らせ • Jan 09+ 1 more updateR1 RCM Inc. to Report Q4, 2023 Results on Feb 27, 2024R1 RCM Inc. announced that they will report Q4, 2023 results on Feb 27, 2024
お知らせ • Dec 20R1 RCM Inc. Appoints Clay Ashdown as DirectorOn December 18, 2023, the Board of Directors of R1 RCM Inc. appointed Clay Ashdown as a director of the Company, effective as of December 18, 2023, to serve until the Company’s 2024 Annual Meeting of Stockholders and thereafter until his successor is duly elected and qualified, or until his earlier death, resignation, or removal. Mr. Ashdown has served as Intermountain’s Chief Financial Officer since October 23, 2023, where he has accountability over all finance and related functions at Intermountain, including finance operations, financial planning, accounting and internal audit, debt and credit management, rating agency/investor relations, payer contracting, revenue cycle, risk management, construction, and real estate. Mr. Ashdown has held numerous roles at Intermountain since joining the organization in 2000 and prior to his current role, Mr. Ashdown served as the Senior Vice President of Finance Operations. Before joining Intermountain, Mr. Ashdown worked at the public accounting firm of KPMG. Mr. Ashdown graduated from the University of Utah with a degree in Accounting and a minor in Russian, and he also earned an MBA from the University of Utah.
お知らせ • Dec 08R1 RCM Inc. (NasdaqGS:RCM) entered into the Purchase Agreement to acquire Acclara Solutions, LLC from Providence St. Joseph Health.R1 RCM Inc. (NasdaqGS:RCM) entered into the Purchase Agreement to acquire Acclara Solutions, LLC from Providence St. Joseph Health for $680 million on December 5, 2023. The consideration for the acquisition will consist of $675 million in cash and the Warrant to purchase up to 12,192,000 shares of the R1 RCM Inc.’s common stock with an exercise price of $10.52 per share. R1 RCM Inc. expects to finance the cash portion of the consideration and the fees and expenses associated with the acquisition with a combination of a new incremental senior secured first lien term loan B facility, cash on hand, and borrowings under the R1 RCM Inc.’s existing revolving credit facility. Concurrently with the signing of the Purchase Agreement, the R1 RCM Inc. entered into that certain commitment letter, dated as of December 5, 2023, with JPMorgan Chase Bank, N.A., Bank of America, N.A., BofA Securities, Inc. and Barclays Bank PLC for an incremental senior secured first lien term loan B facility up to $500 million. The proceeds of the Incremental Term Loan will be used, together with cash on hand and borrowings under the R1 RCM Inc.’s existing revolving credit facility, to finance the cash consideration of the acquisition and related fees and expenses. Acclara generates ~$300M of Revenue(Acclara metrics are for the LTM ended June 30, 2023 inclusive of Advata Q2 2023 annualized.) and ~$25M Adjusted EBITDA(: Acclara metrics are for the LTM ended June 30, 2023 inclusive of Advata Q2 2023 annualized and Includes expected collective synergies or contributions to revenue and Adjusted EBITDA, as applicable, from the acquisition of Acclara and the 10-year agreement with Providence). over the last twelve months. The consummation of the acquisition is subject to certain conditions, including, among other things, the receipt of regulatory approvals, entry into the Commercial Agreements, the expiration or termination of all waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the rules and regulations promulgated thereunder, and other customary closing conditions. The consummation of the acquisition is not subject to approval from the R1 RCM Inc.’s stockholders. The acquisition is expected to close in early 2024. enterview Partners LLC and J.P. Morgan acted as financial advisors to R1, and Perkins Coie LLP, Kirkland & Ellis LLP, and Baker Donelson acted as legal counsel. BDT & MSD Partners acted as financial advisor to Providence, and McDermott Will & Emery and ArentFox Schiff LLP acted as legal counsel.
お知らせ • Nov 19R1 RCM Receives Notice Of Filing Delinquency from NasdaqR1 RCM Inc. announced that, as anticipated, it received a letter from Nasdaq's Listing Qualifications Department indicating that, as a result of the Company's delay in filing its Quarterly Report on Form 10-Q for the three and nine months ended September 30, 2023 (the "Form 10-Q"), the Company no longer complies with the continued listing requirements under Nasdaq Listing Rule 5250(c)(1), which requires Nasdaq-listed companies to timely file all periodic reports with the Securities and Exchange Commission (the "Commission"). On November 13, 2023, the Company filed with the Commission a Notification of Late Filing on Form 12b-25 with respect to the Form 10-Q as a result of its determination to restate certain of its previously issued financial statements. The Nasdaq notice has no immediate effect on the listing of the Company's common stock. The Nasdaq notice states that the Company is required to submit a plan to regain compliance with Nasdaq's filing requirements for continued listing within 60 calendar days of the date of the notice. Upon acceptance of the Company's compliance plan, Nasdaq is permitted to grant an extension of up to 180 days from the Form 10-Q's filing due date for the Company to regain compliance with Nasdaq's filing requirements for continued listing. The Company intends to file the Form 10-Q with the Commission as soon as practicable.
お知らせ • Nov 14R1 RCM Inc. announced delayed 10-Q filingOn 11/13/2023, R1 RCM Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
Price Target Changed • Nov 03Price target decreased by 8.8% to US$19.53Down from US$21.41, the current price target is an average from 16 analysts. New target price is 69% above last closing price of US$11.53. Stock is down 22% over the past year. The company is forecast to post earnings per share of US$0.046 next year compared to a net loss per share of US$0.16 last year.
お知らせ • Nov 03R1 RCM Inc. Provides Revenue Guidance for the Year 2023R1 RCM Inc. provided revenue guidance for the year 2023. For the year, the company expects Revenue of $2,255 million to $2,275 million.
Reported Earnings • Nov 03Third quarter 2023 earnings released: EPS: US$0.003 (vs US$0.071 loss in 3Q 2022)Third quarter 2023 results: EPS: US$0.003 (up from US$0.071 loss in 3Q 2022). Revenue: US$572.8m (up 16% from 3Q 2022). Net income: US$1.30m (up US$30.8m from 3Q 2022). Profit margin: 0.2% (up from net loss in 3Q 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 7.0% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
Buying Opportunity • Nov 02Now 26% undervalued after recent price dropOver the last 90 days, the stock is down 37%. The fair value is estimated to be US$14.76, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Meanwhile, the company became loss making.
お知らせ • Oct 26R1 RCM Inc. Announces Janie Wade Resigns from its Board of DirectorsR1 RCM Inc. announced on October 19, 2023, the company received notice that Janie Wade will be resigning from the board of directors of the Company, effective October 21, 2023, in connection with her resignation from Intermountain Health. Ms. Wade was nominated to the Board by IHC Health Services Inc. (Intermountain) pursuant to the Securities Purchase Agreement, dated as of January 23, 2018, between the Company and Intermountain. Under the terms of the Securities Purchase Agreement, Intermountain is entitled to nominate another individual to the Board upon Ms. Wade’s resignation.
Buying Opportunity • Oct 18Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 35%. The fair value is estimated to be US$14.65, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Meanwhile, the company became loss making.
お知らせ • Oct 17R1 RCM Inc. to Report Q3, 2023 Results on Nov 02, 2023R1 RCM Inc. announced that they will report Q3, 2023 results Pre-Market on Nov 02, 2023
Recent Insider Transactions Derivative • Aug 10Lead Independent Director notifies of intention to sell stockJohn Henneman intends to sell 50k shares in the next 90 days after lodging an Intent To Sell Form on the 8th of August. If the sale is conducted around the recent share price of US$17.17, it would amount to US$859k. Since September 2022, John's direct individual holding has increased from 49.60k shares to 54.75k. Company insiders have collectively sold US$16m more than they bought, via options and on-market transactions in the last 12 months.
Price Target Changed • Aug 07Price target increased by 7.8% to US$21.70Up from US$20.13, the current price target is an average from 15 analysts. New target price is 25% above last closing price of US$17.38. Stock is down 35% over the past year. The company is forecast to post earnings per share of US$0.064 next year compared to a net loss per share of US$0.16 last year.
お知らせ • Aug 03R1 RCM Inc. Provides Earnings Guidance for the Year of 2023R1 RCM Inc. provided earnings guidance for the year of 2023. For the year, company expects Revenue of between $2,255 million and $2,275 million and GAAP operating income of $140 million to $155 million.
Reported Earnings • Aug 02Second quarter 2023 earnings released: EPS: US$0.001 (vs US$0.069 loss in 2Q 2022)Second quarter 2023 results: EPS: US$0.001 (up from US$0.069 loss in 2Q 2022). Revenue: US$560.7m (up 43% from 2Q 2022). Net income: US$300.0k (up US$20.7m from 2Q 2022). Profit margin: 0.1% (up from net loss in 2Q 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 6.9% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.
お知らせ • Jul 13R1 RCM Inc. to Report Q2, 2023 Results on Aug 02, 2023R1 RCM Inc. announced that they will report Q2, 2023 results Pre-Market on Aug 02, 2023
Recent Insider Transactions • Jun 16Senior VP recently sold US$487k worth of stockOn the 12th of June, Richard Evans sold around 29k shares on-market at roughly US$16.78 per share. This transaction amounted to 20% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$3.1m more than they bought in the last 12 months.
Recent Insider Transactions • May 15President recently sold US$327k worth of stockOn the 10th of May, John Sparby sold around 20k shares on-market at roughly US$16.36 per share. This transaction amounted to 7.8% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. John has been a net seller over the last 12 months, reducing personal holdings by US$2.1m.
Recent Insider Transactions Derivative • May 14President notifies of intention to sell stockJohn Sparby intends to sell 20k shares in the next 90 days after lodging an Intent To Sell Form on the 10th of May. If the sale is conducted around the recent share price of US$15.71, it would amount to US$314k. Since September 2022, John's direct individual holding has increased from 163.82k shares to 254.82k. Company insiders have collectively sold US$18m more than they bought, via options and on-market transactions in the last 12 months.
お知らせ • May 05R1 RCM Inc. Provides Earnings Guidance for the Year 2023R1 RCM Inc. provided earnings guidance for the year 2023. For the period, Company expects Revenue of between $2,280 million and $2,330 million. GAAP operating income of $115 million to $140 million.
Reported Earnings • May 05First quarter 2023 earnings: EPS exceeds analyst expectationsFirst quarter 2023 results: EPS: US$0.001 (down from US$0.10 in 1Q 2022). Revenue: US$545.6m (up 42% from 1Q 2022). Net income: US$300.0k (down 99% from 1Q 2022). Profit margin: 0.1% (down from 7.6% in 1Q 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) exceeded analyst estimates. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 7.3% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 18% per year, which means it is tracking significantly ahead of earnings growth.
Recent Insider Transactions • Feb 23CEO & Director recently bought US$1.0m worth of stockOn the 21st of February, Lee Rivas bought around 72k shares on-market at roughly US$13.93 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was Lee's only on-market trade for the last 12 months.
Reported Earnings • Feb 17Full year 2022 earnings: EPS misses analyst expectationsFull year 2022 results: US$0.16 loss per share (improved from US$1.86 loss in FY 2021). Revenue: US$1.81b (up 23% from FY 2021). Net loss: US$57.6m (loss narrowed 88% from FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 18%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 7.5% growth forecast for the Healthcare industry in the US. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has remained flat, which means it is well ahead of earnings.
お知らせ • Feb 17R1 RCM Inc. Provides Earnings Guidance for the Fiscal Year 2023R1 RCM Inc. provided earnings guidance for the fiscal year 2023. for the year, the company expects revenue of between $2,280 million and $2,330 million and GAAP operating income of $115 million to $140 million.
Price Target Changed • Feb 16Price target increased by 7.3% to US$16.18Up from US$15.07, the current price target is an average from 14 analysts. New target price is 11% above last closing price of US$14.57. Stock is down 43% over the past year. The company is forecast to post a net loss per share of US$0.14 next year compared to a net loss per share of US$1.86 last year.
お知らせ • Jan 27R1 RCM Inc. to Report Q4, 2022 Results on Feb 16, 2023R1 RCM Inc. announced that they will report Q4, 2022 results Pre-Market on Feb 16, 2023
Major Estimate Revision • Jan 08Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 expected loss increased from -US$0.06 to -US$0.07 per share. Revenue forecast of US$1.79b unchanged since last update. Healthcare industry in the US expected to see average net income growth of 4.8% next year. Consensus price target up from US$14.00 to US$14.57. Share price rose 14% to US$12.43 over the past week.
お知らせ • Jan 06+ 2 more updatesR1 RCM Inc. Announces Chief Financial Officer ChangesR1 RCM Inc. announced the appointments of Jennifer Williams as Chief Financial Officer, effective immediately. Ms. Williams will succeed Rachel Wilson who will step down from their role and remain with the Company in advisory roles to ensure a seamless transition. Ms. Williams, who previously served as Chief Financial Officer of Cloudmed, brings more than 20 years of financial planning, accounting, M&A and operational finance leadership experience across several healthcare revenue management, data analytics and technology businesses, including Change Healthcare, First Advantage, LexisNexis Risk Solutions and Ernst & Young. During her career, she has led several growth transformations, large scale integrations and an initial public offering. Jennifer Williams joined R1 following the acquisition of Cloudmed, where she served as Chief Financial Officer since July 2020. Prior to Cloudmed, Ms. Williams served as Senior Vice President and Chief Financial Officer of Corporate functions for Change Healthcare. Earlier in her career, she was the corporate controller and global finance leader at First Advantage and held financial leadership positions at LexisNexis Risk Solutions for over 10 years. She began her career with Ernst & Young. Ms. Williams has a B.S. and Master of Accountancy degrees from Auburn University and is a certified public accountant.
Price Target Changed • Nov 16Price target decreased to US$15.55Down from US$30.73, the current price target is an average from 11 analysts. New target price is 71% above last closing price of US$9.07. Stock is down 65% over the past year. The company is forecast to post a net loss per share of US$0.057 next year compared to a net loss per share of US$1.86 last year.
Price Target Changed • Nov 10Price target decreased to US$27.82Down from US$31.90, the current price target is an average from 11 analysts. New target price is 303% above last closing price of US$6.90. Stock is down 73% over the past year. The company is forecast to post a net loss per share of US$0.04 next year compared to a net loss per share of US$1.86 last year.